Why Patients Switch Between These Weight Loss Treatments
Understanding the Switch from Mounjaro to 1mg Wegovy
When comparing 1mg of Wegovy to Mounjaro, the most significant difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors. Many patients switch between these prescription-only medicines for various reasons including cost considerations, side effect profiles, or availability concerns. The 1mg dose represents weeks 9-12 of the Wegovy escalation schedule, where patients typically experience established appetite regulation and measurable results from their weight management journey.
Switching from Mounjaro to 1mg Wegovy requires careful consideration of dose equivalence and timing. While direct dose conversions aren't standardised, your prescriber will assess your current Mounjaro dose and treatment response to determine the appropriate Wegovy starting point. Some patients may need to begin at 0.5mg and escalate to 1mg, while others already on higher Mounjaro doses might start directly at 1mg. EverydayMeds' clinical team works with your prescriber to ensure a smooth transition, maintaining your treatment momentum while switching between these effective weight management medications.
Cost Comparison: 1mg Wegovy vs Mounjaro Pricing
The financial aspect of comparing 1mg of Wegovy to Mounjaro often influences switching decisions. Our 1mg Wegovy pen costs £99.99 after applying discount codes (FIRST40 for new customers, DOSE25 for returning customers) at checkout. This pricing includes full clinical assessment, prescriber review, and next-day cold-chain delivery to your door. For patients requiring consistent dosing, our Consistency 1mg bundle provides two pens for £209.99, offering convenience and Reliable Supply continuity without multiple ordering processes.
Many patients find switching to Wegovy from Mounjaro offers significant cost advantages, particularly when utilising our bundle options. The Advance Duo (1mg + 1.7mg) at £269.99 bridges you to higher doses while maintaining treatment progression. Unlike some pharmacies that charge separately for consultations, assessments, or delivery, our prices include comprehensive clinical support from our GPhC-registered pharmacy (#9012878). This transparent pricing structure helps patients budget effectively for their long-term weight management journey without unexpected additional costs.
Clinical Evidence Supporting 1mg Wegovy Compared to Mounjaro
When evaluating 1mg of Wegovy compared to Mounjaro, both medications demonstrate robust clinical evidence in separate trial programmes. Wegovy's efficacy was established in the landmark STEP trials, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The 1mg dose represents a crucial midpoint in the escalation schedule where patients typically begin experiencing significant appetite suppression and portion control benefits.
Mounjaro's SURMOUNT trials demonstrated its own efficacy profile, though direct head-to-head comparisons between these medications remain limited due to different trial designs and patient populations. Both treatments require prescription oversight and work most effectively when combined with lifestyle modifications. Your prescriber can help determine which medication may be more suitable based on your individual health profile, treatment goals, and response to previous therapies.
How 1mg Wegovy Works in Your Weight Management Journey
Understanding how 1mg of Wegovy compared to Mounjaro works mechanistically helps explain why some patients prefer switching between treatments. Wegovy contains semaglutide, which mimics the natural GLP-1 hormone that regulates appetite and food intake. At the 1mg dose level, patients typically experience established appetite reduction, increased feelings of fullness after smaller meals, and reduced food cravings as the medication works on brain appetite centres. This dose represents the midpoint of escalation where many patients report noticeable changes in their eating patterns and relationship with food. The once-weekly injection schedule provides consistent medication levels, supporting sustainable weight management alongside dietary changes and increased physical activity.
Ordering Process: Switching Made Simple at EverydayMeds
Switching from Mounjaro to 1mg Wegovy through EverydayMeds involves a streamlined three-step process designed for patient safety and convenience. First, complete our 3-minute online clinical assessment, providing details about your current Mounjaro treatment, dose, duration, and any side effects experienced. Our clinical team reviews your information alongside your medical history to ensure Wegovy is appropriate for your continued weight management journey. The prescriber review typically takes three working days (or 24 hours with our express service), during which we may contact you for additional information about your treatment transition. Once approved, your 1mg Wegovy pen ships via next-day delivery in temperature-controlled packaging, ensuring medication integrity from our GPhC-registered facility (#9012878) directly to your door.
Storage Advantages When Comparing 1mg Wegovy to Mounjaro
Storage considerations represent a practical advantage when comparing 1mg of Wegovy to Mounjaro for many patients. Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy more convenient for travel, work schedules, or situations where refrigeration access is limited. Both medications require initial refrigerated storage at 2-8°C before first use, and both utilise user-friendly injection pens. The Wegovy FlexTouch pen system provides clear dose indication and simple injection technique, similar to other modern injection devices patients may be familiar with from their Mounjaro experience.
Personalised Switching Strategy for 1mg Wegovy vs Mounjaro
Every patient's experience with switching from Mounjaro to 1mg Wegovy differs based on individual factors including current dose, treatment duration, side effect experience, and weight loss progress. Some patients switch due to gastrointestinal side effects with their current medication, hoping for better tolerability with a different mechanism of action. Others may find Mounjaro's dual-receptor approach too strong and prefer Wegovy's GLP-1-only mechanism for more gradual appetite regulation.
Cost considerations often drive switching decisions, particularly for patients paying privately or those whose insurance coverage changes. The availability factor also influences switches, as supply issues can temporarily affect either medication. EverydayMeds maintains stock of both treatments, allowing flexibility in your weight management journey. Our clinical team coordinates with prescribers to ensure switching protocols maintain your treatment momentum while optimising tolerability and effectiveness for your individual circumstances.
Making Your Decision: Expert Support Available
Choosing between continuing Mounjaro or switching to 1mg Wegovy requires expert guidance tailored to your specific situation. EverydayMeds provides comprehensive support throughout the decision-making and switching process, from initial consultation through ongoing treatment monitoring. Use discount code FIRST40 for new customers or DOSE25 for returning customers at checkout to access our competitive pricing. Our clinical team remains available for questions about timing, side effect management, or dose adjustments during your transition. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment, knowing you're supported by the UK's most trusted weight management pharmacy. Both Wegovy and Mounjaro represent effective treatment options, and our expert prescribers can help determine which aligns best with your individual needs, goals, and circumstances for long-term success.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
